Margenza (margetuximab-cmkb) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed October 6, 2026.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. 4

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine